<DOC>
	<DOC>NCT02562183</DOC>
	<brief_summary>In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute cerebral infarction ,a multi-center, open label , single group study was designed. Expect to enroll 60 sites and 2186 subjects. Subjects will receive a treatment of 21 days with kallikrein and 90 days follow-up.</brief_summary>
	<brief_title>The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Kallikreins</mesh_term>
	<criteria>1. Acute anterior circulation cerebral infarction diagnosed ≤ 48h; 2. First time diagnosed or have history of acute anterior circulation cerebral infarction without serious sequelae(mRS=02); 3. Age from 18 to 80 years old; 4. National Institute of Health stroke scale(NIHSS) from 6 to 25; 5. Have provided signed written informed consent from the patient or the patient's legal representative. 1. Brain CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid hemorrhage, etc. 2. Transient ischemic attack(TIA); 3. Serious disturbance of consciousness: Glasgow Coma ScaleGCS（GCS）≤8; 4. Combined angiotensinconverting enzyme inhibitor(ACEI) less than 5 halftime(according to its instruction), or need to be treated with ACEI; 5. Cases treated with thrombolysis / stent surgery or expected to be treated with thrombolysis / interventional therapy / stent surgery.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>